Goodwin Biotechnology, Aspyrian Therapeutics Collaborate on Innovative Antibody Drug Conjugate
News Mar 25, 2014
Goodwin Biotechnology, Inc. announced the agreement with Aspyrian Therapeutics, Inc. for use in Phase I clinical trials
Aspyrian Therapeutics has secured an exclusive license from the National Cancer Institute for a new ADC technology platform, Near ‐ infrared Photoimmunotherapy (PIT), which permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor. Because the payload in this unique ADC is inert until it is both in the tumor and activated by near ‐ infrared (NIR) light, it overcomes the dose ‐ limiting adverse effects that have hindered the development of conventional, toxin ‐ loaded ADC systems.
“We are pleased to have been selected to partner with Aspyrian Therapeutics for this leading edge ADC project,” said SooYoung Lee, PhD, Chief Operating Officer at Goodwin Biotechnology. “This important project is a testament to our experience and expertise in bioconjugation that has been developed and refined over more than a decade. This initiative has been led by Muctarr Sesay, PhD, Vice President of Process Development who is one of the pioneers in process development and cGMP manufacturing of many ADCs and biologic drug conjugates, which Goodwin has successfully manufactured for human clinical studies.”
“The technical expertise that Goodwin Biotechnology offers in the field of bioconjugation, coupled with the responsiveness and flexibility they exhibited during the selection process, made them the obvious choice,” noted Miguel Garcia ‐ Guzman, PhD, Chief Scientific Officer at Aspyrian Therapeutics. “Our mission is to leverage the potential of the PIT platform by developing a pipeline of proprietary and partnered ADC products, and this collaboration represents a critical milestone in this endeavor.”
Near ‐ infrared Photoimmunotherapy (PIT) is based on three components: 1. An antibody that binds to cell ‐ surface antigens. 2. The NIR IR700DX dye conjugated to the antibody via a stable linkage. 3. NIR light dosimetry to activate the conjugate (cell killing occurs whether the conjugate is surface ‐ bound or internalized).
Upon administration of non ‐ ionizing NIR light, PIT induces rapid cell killing by localized disruption of cell membranes of only those cells targeted by the antibody conjugate. Importantly, unbound conjugates and free dye do not elicit any phototoxicity upon NIR irradiation. The combination of selective binding to surface antigens and organ ‐ localized NIR activation permits highly efficacious disease ‐ specific ablation, while sparing nearby healthy tissues and structures.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE